SCHEMBL6795144

SCHEMBL6795144

C[C@@H](NC(=O)c1ccccn1)c1ccc(N)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.61
HTT P42858 4/20 0.51
KDM4E B2RXH2 3/20 0.51
ALDH1A1 P00352 2/20 0.51
NPC1 O15118 1/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.51
RAB9A P51151 1/20 0.51
PHGDH O43175 1/20 0.50
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49
HDAC5 Q9UQL6 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27583365 1.00 ACACB (0.61) ACACBHTTKDM4EALDH1A1NPC1
SCHEMBL6792182 1.00 ACACB (0.61) ACACBHTTKDM4EALDH1A1NPC1
SCHEMBL31739150 0.83 ACACB (0.69) ACACBHTTKDM4EALDH1A1NPC1
SCHEMBL31739129 0.82 PDE2A (0.61) ACACBPDE2ATLR7
SCHEMBL27583336 0.81 ACACB (0.57) ACACBHTTKDM4EALDH1A1RAB9A
SCHEMBL6789222 0.81 ACACB (0.57) ACACBHTTKDM4EALDH1A1RAB9A
SCHEMBL6794110 0.81 ACACB (0.57) ACACBHTTKDM4EALDH1A1RAB9A
SCHEMBL28596533 0.80 HIF1A (0.57) ACACBPHGDHROCK2RPS6KA5MAP4K4
SCHEMBL12001226 0.78 ACACB (0.83) ACACBKDM4ENPC1PKMRAB9A
SCHEMBL1106971 0.78 KDM4E (0.63) ACACBHTTKDM4EALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed
CN-1478077-A Benzamide compounds as APO B secretion inhibitors ����ҩƷ��ҵ��ʽ���� 2004-02-25 CN disclosed
EP-1326835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-16 EP disclosed
WO-2002028835-A1 BENZAMIDE COMPOUNDS AS APO B SECRETION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-04-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 ACACB 104/4885HTT 2566/4885KDM4E 3114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.